Ensoma Focuses on Key Gene Therapy, Cuts Staff
Ensoma reduces its workforce again and halts other projects to prioritize its main gene therapy for a rare immune disease.
Biotech company Ensoma makes big changes. The company cut staff for the second time. It also stopped some early-stage research. Ensoma now focuses on one important gene therapy. This therapy treats a rare immune disease.
Ensoma believes in this main project. The company made similar cuts in November. They cut their workforce in half then. These new cuts show how serious Ensoma is about its lead drug.
Ensoma's choices are common in biotech. Companies often choose one strong project. They put all their effort there. This can help them succeed. It means they must stop other projects.
This news shows Ensoma's path. They aim to bring this one important therapy to patients. This focused plan could help the company reach its goal faster.
Source: FierceBiotech
More from Biotech
